Nicole Drezner

FDA Approval Summary: Sotorasib for <i>KRAS G12C</i> -Mutated Metastatic NSCLC

Erica C. Nakajima, Nicole Drezner, Xiaoxue Li et al. · Clinical Cancer Research · 2021 · 293 citations · Full text

Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.

Oladimeji Akinboro, Jonathon Vallejo, Erica C. Nakajima et al. · Journal of Clinical Oncology · 2022 · 77 citations

FDA Approval Summary: Dabrafenib in Combination with Trametinib for <i>BRAF</i>V600E Mutation–Positive Low-Grade Glioma

Michael I. Barbato, Jeannette Nashed, Diana Bradford et al. · Clinical Cancer Research · 2023 · 59 citations · Full text

FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review

Abigail L. Koch, Paz J. Vellanki, Nicole Drezner et al. · Clinical Cancer Research · 2021 · 58 citations · Full text

Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.

Erica C. Nakajima, Yi Ren, Jonathon Vallejo et al. · Journal of Clinical Oncology · 2022 · 54 citations

Advanced Nsclc, Pd-l1 Expression, Medicine +15